Immunoglobulin A nephropathy (IgAN), also known as Berger’s disease, is a rare autoimmune disease affecting the kidneys. It is characterized by predominant IgA protein deposition and impairment of blood filtration in the kidneys’ tiny blood channels. The IgAN drug market comprises supportive treatments such as antihypertensive drugs, immunosuppressants, and diuretics. The only approved therapy for IgAN is Tarpeyo (a delayed-release budesonide capsule). High unmet need exists for effective treatments that can meaningfully delay or halt this progressive end-stage kidney disease. The future of the IgAN market is bright owing to emerging therapies such as sparsentan (Travere Therapeutics), iptacopan (Novartis), narsoplimab (Omeros), atrasentan (Chinook Therapeutics), and sibeprenlimab (Otsuka). Supported by insights from thought leaders, we analyze the challenges and opportunities for new drugs to treat an increasingly dynamic and complex disease. Understanding the current and future competitive landscape is critical for marketers to secure market share and carve out a clinical niche.
Questions answered
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancements
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold. Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.